EU ORPHAN DRUGS BODY LOOKS TO HELP PHARMA COMPANIES PROSPER FROM THEIR INNOVATION

THE EUROPEAN Medicines Agency’s committee for orphan medicinal products is trying to encourage pharmaceutical companies to make such drugs by pointing out how they can source sales from health services. The committee has started working closely with EUnetHTA, an organisation that promotes scientific cooperation amongst Europe-based health technology assessments. HTA bodies recommend which medicines can be paid for or reimbursed by European Union national healthcare systems. So together, EMA and the EUnetHTA are “working towards a better understanding on ...


Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.